Clinical trial · Observational
Development and Application of Patient-Derived Models of Cancer
Beyond Genomics Functional Precision Oncology Research Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this observational study is to evaluate the clinical utility of investigational patient-derived cancer models, to assess the performance of biomarker-based therapeutic predictions in the patient-derived models. Each participant in the observational study will have a piece of cancer removed as part of routine, physician direct care and grown in laboratory mice, where multiple anti-cancer drugs can be tested on it simultaneously. Additional data will be provided to the oncologist; interpretation of the results and any clinical actions are at the sole discretion of the oncologist.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- PDX Tumor Growth
- timeFrame
- 180 days
- description
- The primary outcome of this study is the successful engraftment of patient-derived xenograft (PDX) tumors in the study animals. Engraftment success will be assessed by quantifying tumor growth using caliper measurements and/or magnetic resonance imaging (MRI). Successful engraftment will be defined as measurable and sustained tumor growth consistent with the characteristics of the original patient tumor.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Solid tumor patients stage 2-4. * Cancer patients who have been previously treated or shown resistance or refraction to standard-of-care therapies and where the implicated tissue has not been irradiated in the ten (10) weeks prior to excision. * Patients with tumors are amenable to biopsy or surgery for fresh tissue and blood procurement as part of routine clinical care * Patients must be referred by a healthcare professional * Willingness for tissue samples used in future research * Signed informed consent * Willingness to share diagnosis, available genetic/molecular profiling data, treatment history, and treatment outcome monitoring Exclusion Criteria: * Failure to provide informed consent * Inaccessible tumors for biopsy or unavailability of tumor tissue for research purposes * Subjects under the age of 18 * Subjects with cognitive impairment * Pregnant subjects * Contraindications to undergoing a biopsy procedure * No prior treatments, naive
References
Publications (0)
Data not yet available